Role of Bumetanide in Treatment of Autism

Launched by SHERIEF ABD-ELSALAM · Feb 19, 2021

Keywords

ClinConnect Summary

This clinical trial is investigating the use of a medication called bumetanide to see how it can help children with autism. The study aims to understand if this drug can improve symptoms in kids diagnosed with Autism Spectrum Disorder (ASD), specifically those between the ages of 3 and 12. To participate, children must have a certain level of autism severity, as measured by a specific rating scale.

If your child is eligible, they will be part of a research group that is actively recruiting participants. It’s important to note that children with certain medical conditions, such as epilepsy or significant heart issues, will not be able to join. Participants will receive the study medication and will be monitored by healthcare professionals throughout the trial. This study is a chance to contribute to important research that may lead to better treatment options for children with autism.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. All patients with ASD diagnosed by CARS rating Scale⩾30.
• • 2. Age of patients range between (3-12) years.
• Exclusion Criteria:
• • Patients with ASD associated with neurological antecedents (including epilepsies and febrile seizures), hepatic, renal dysfunction or electrocardiogram abnormalities and syndromatic children(Rett).